Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cardiovascular disease

Highlights from the ACR Review Course 2022

Samantha C. Shapiro, MD  |  December 6, 2022

PHILADELPHIA—At ACR Convergence 2022, the much-anticipated ACR Review Course featured talks from eight experts. Topics reflected the heterogeneity of our field and included Sjögren’s disease, spondyloarthritis (SpA), osteoarthritis (OA), paraneoplastic rheumatic syndromes, metabolic bone disease, statin myopathy, Raynaud’s phenomenon and autoinflammatory syndrome. Here, I share highlights from this comprehensive, six-hour session. Sjögren’s Disease Sara S….

Filed under:ACR ConvergenceConditionsMeeting ReportsOsteoarthritis and Bone DisordersOther Rheumatic ConditionsSjögren’s Disease Tagged with:ACR Convergence 2022ACR Convergence 2022 – ASautoinflammatory diseasemetabolic bone diseaseosteoarthritis (OA)paraneoplastic rheumatic syndromesRaynaud’s phenomenonSjogren'sspondyloarthritis (SpA)statin myopathy

String of Pearls: Lessons in Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  December 6, 2022

PHILADELPHIA—William “Bill” R. Palmer, MD, MACR, was the first board-certified rheumatologist in Omaha, Neb., where he spent his entire 43-year clinical career and established himself as a great clinician, mentor and educator. Although Dr. Palmer passed away from metastatic thyroid cancer in August 2021, his memory lives on through his physician colleagues and at ACR…

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2022Rheumatoid arthritisRheumatoid Arthritis (RA)

To Treat or Not to Treat? The Great Debate on Treatment of Subclinical Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  December 6, 2022

PHILADELPHIA—One of the great advancements in the field of rheumatology in recent years has been the increased understanding of various stages of disease in rheumatoid arthritis (RA), including what is termed subclinical rheumatoid arthritis. However, questions remain regarding whether to treat patients with subclinical disease and whether treatment of these patients has implications in preventing…

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2022pre-rheumatoid arthritisRheumatoid arthritis

Psoriatic Arthritis & the Obese Patient

Linda Kossoff  |  November 6, 2022

Estimates from the National Psoriasis Foundation indicate that more than 8 million people in the U.S. suffer from psoriasis and that approximately 30% of those individuals develop psoriatic arthritis (PsA).1 Given these statistics, roughly 2.4 million people in the country are likely affected by PsA. Moreover, patients with this systemic condition carry a higher-than-average burden…

Filed under:ConditionsPatient PerspectivePsoriatic Arthritis Tagged with:ObesityPsoriatic Arthritis

Healthy Lifestyle Behaviors Lower Women’s Risk of Developing Rheumatoid Arthritis

Lara C. Pullen, PhD  |  August 25, 2022

Using data from cohorts with detailed lifestyle data and lengthy follow-up, Hahn et al. demonstrated that healthy lifestyle behaviors are associated with a lower risk of developing rheumatoid arthritis (RA), concluding that a substantial proportion of RA may be preventable.

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis Care & ResearchbehaviorDietlifestylephysical activityphysical fitnessRheumatoid Arthritis (RA)

Late Summer 2022’s Awards, Appointments & Announcements in Rheumatology

Gretchen Henkel  |  August 14, 2022

Charles G. Helmick III, MD, Retires After 42 Years with the CDC On Dec. 31, 2021, after 42 years of service, Charles (Chad) G. Helmick III, MD (Capt., USPHS, Ret.), officially retired from the Centers for Disease Control and Prevention. He joined the CDC in 1979, when Jimmy Carter was president, and served through eight…

Filed under:AwardsProfessional TopicsProfiles Tagged with:Dr. Amanda S. AlexanderDr. Cecilia ChungDr. Charles G. Helmick

A Guiding Light for RA: Insights into Clinical Decision Making, Drug Safety & More

Jason Liebowitz, MD, FACR  |  August 11, 2022

The treatment and management of rheumatoid arthritis (RA) is ever evolving. Here Clifton O. Bingham, MD, discusses the application of RA guidelines, the most recent drug safety information and more.

Filed under:ConditionsMeeting ReportsRheumatoid Arthritis Tagged with:Annual Advances in the Diagnosis & Treatment of the Rheumatic DiseasesDrug SafetyGuidelinesJAK inhibitorsRheumatoid Arthritis (RA)

Updates on PsA: Insights into the Latest Psoriatic Arthritis Treatments & Research

Jason Liebowitz, MD, FACR  |  August 11, 2022

Ana-Maria Orbai, MD, MHS, addressed the latest research into psoriatic arthritis (PsA), including a comprehensive overview of the latest FDA-approved treatments and their implications for clinical practice.

Filed under:ConditionsMeeting ReportsPsoriatic Arthritis Tagged with:Annual Advances in the Diagnosis and Treatment of the Rheumatic DiseasesPsoriatic Arthritisrisankizumabupadacitinib

Clinical Challenges in SLE: Glucocorticoids—How Much Is Too Much?

Samantha C. Shapiro, MD  |  July 22, 2022

Glucocorticoids remain a prominent part of care for many patients with SLE but can have toxic side effects; this EULAR 2022 session discussed one institution’s approach to lower the dosage.

Filed under:ConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:GlucocorticoidsHCQHydroxychloroquine (HCQ)prednisoneSLEsystemic lupus erythematosus (SLE)

Predicting the Future: Prognostication in Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  July 19, 2022

A EULAR 2022 abstract session looked at several studies that seek to increase understanding of RA pathogenesis & identify patients at risk for disease progression.

Filed under:ConditionsEULAR/OtherMeeting ReportsRheumatoid Arthritis Tagged with:anti-advanced glycated end-products (anti-AGE) antibodiesanti-malondialdehyde-acetaldehyde (anti-MAA) antibodiesEULARRheumatoid Arthritis (RA)synovialTenosynovitis

  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 64
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences